<DOC>
	<DOCNO>NCT00410124</DOCNO>
	<brief_summary>To assess whether daily treatment RAD001 could slow growth spread metastatic carcinoma kidney . The safety RAD001 also study trial .</brief_summary>
	<brief_title>RAD001 Plus Best Supportive Care ( BSC ) Versus BSC Plus Placebo Patients With Metastatic Carcinoma Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients metastatic carcinoma histological cytological confirmation clear cell RCC ( tissue original diagnosis renal cell cancer acceptable ) . The date progression sunitinib and/or sorafenib must within 6 month . Patients may receive one agent Prior therapy cytokine ( i.e. , IL2 , Interferon ) and/or VEGFligand inhibitor ( i.e. , bevacizumab ) permit . Prior vaccine therapy adjuvant setting permit . Patients least one measurable lesion baseline per Response evaluation criterion solid tumor ( RECIST ) criterion , either physical exam determine Computer Tomography ( CT ) Scan Magnetic Resonance Imaging ( MRI ) . Patients Karnofsky Performance Status ≥70 % . Adequate bone marrow , liver renal function . Patients life expectancy ≥ 3 month . Women childbearing potential must negative serum urine pregnancy test 48 hour prior administration first study treatment . Patients give write informed consent obtain accord local guideline Patients currently receive chemotherapy , immunotherapy , radiotherapy receive within 4 week study entry Patients previously receive mTOR inhibitor . Patients know hypersensitivity RAD001 rapamycins ( sirolimus , temsirolimus ) excipients . Patients untreated CNS metastasis neurologically unstable despite treatment CNS metastasis . ( Patients treat CNS metastasis , neurologically stable corticosteroid , eligible enter study ) . Patients receive chronic treatment corticosteroid another immunosuppressive agent Patients know history HIV seropositivity . Patients active , bleed diathesis oral antivitamin K medication ( except low dose coumadin ) Patients severe and/or uncontrolled medical condition Patients history another primary malignancy ≤ 3 year , exception nonmelanoma skin cancer , carcinoma situ uterine cervix Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex . Patients use investigational agent receive investigational drug ≤ 4 week prior randomization Patients unwilling unable comply protocol Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>advanced kidney cancer</keyword>
	<keyword>everolimus</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>oral therapy</keyword>
</DOC>